Northwestern University: Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois 60611-2941
2 studies enrolling now · 29 studies all time
What they study most
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Advanced Malignancies, All Malignancies, Angioimmunoblastic T-cell Lymphoma, Bladder Carcinoma, Breast Cancer, Cancer Weight Loss, Conventional Chondrosarcoma, Cutaneous T-Cell Lymphoma, Unspecified, Cutaneous T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma
Studies at this site
- Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy — Recruiting now
- Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma — Recruiting now
- Study of INBRX-109 in Conventional Chondrosarcoma — Running, not enrolling
- Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma — Running, not enrolling
- A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer — Stopped early
- AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) — Completed
- Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels — Completed
- Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants — Stopped early
- Phase 1/2 Study of S-1 and Cisplatin in Advanced Gastric Cancer — Completed
- SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) — Completed
- First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma — Stopped early
- Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC — Stopped early
- BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma — Completed
- A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer — Stopped early
- Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL) — Stopped early
- VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer — Completed
- Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas — Completed
- Ruxolitinib Prior to Transplant in Patients With Myelofibrosis — Stopped early
- Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors — Completed
- First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia — Stopped early
- Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma — Completed
- Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML) — Completed
- Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma — Completed
- Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free — Completed
- MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients — Stopped early
- Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma — Status unconfirmed
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy — Completed
- A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash — Stopped early
- Amonafide in Combination With Cytarabine in Secondary AML — Completed